Indian heart journal
-
Indian heart journal · Jul 2007
Randomized Controlled TrialEfficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) is a life threatening disease for which phosphodiesterase-5 inhibitor sildenafil is recently approved. We aimed to evaluate the efficacy and safety of tadalafil, a long acting congener of sildenafil, in treatment of PAH related to previous left to right shunt lesions. ⋯ Tadalafil, in patients with PAH related to previous congenital left to right shunt lesions, lead to a significant improvement in exercise capacity (6MWD), PASP and WHO Class with reduced perceived exertion and was well tolerated.
-
Indian heart journal · May 2007
LV based pacing in patients with heart failure and a narrow QRS--an acute hemodynamic study.
Biventricular pacing is beneficial in refractory systolic heart failure having QRS duration more than 130 msec by improving regional dysynchrony and decreasing diastolic mitral regurgitation. Current data show significant systolic dysynchrony in symptomatic systolic heart failure patients out of which nearly 40% have a QRS duration of less than 120 msec. Our study aims at assessing acute hemo-dynamic impact of Biventricular (BiV) and compare it with isolated left ventricular (LV) pacing in patients of systolic heart failure and QRS duration < or = 120 msec. ⋯ BiV pacing, and not LV pacing, benefits patients of systolic heart failure (EF < or = 35%) and narrow QRS (< or = 120 msec) on surface ECG.
-
Indian heart journal · Mar 2007
ReviewLate stent thrombosis with drug-eluting stents: the price to pay to prevent restenosis?
Drug-eluting stents have revolutionized the management of patients with coronary artery disease by decreasing the incidence of restenosis and the need for repeat revascularization. Recent data indicate that they may, however, be associated with a small but significant increase in the risk of late stent thrombosis compared with bare-metal stents. ⋯ Drug-eluting stent implantation needs to be carefully considered in every patient, and the risk of stent thrombosis and bleeding needs to be weighed against the risk of restenosis. Current guidelines recommend that dual antiplatelet therapy should be continued for at least 1 year following drug-eluting stent implantation, although the optimal duration of therapy is yet unknown.
-
Indian heart journal · Mar 2007
Historical ArticleInterventional cardiology: the past, present, and the future.